As CEO of the Dana-Farber Cancer Institute, Laurie Glimcher isn’t afraid to shake things up. She made big waves last year when the institute announced that it was ending its 30-year partnership with Brigham & Women’s Hospital in favor of a deal to build a $1.6 billion cancer hospital with Beth Israel Deaconess Medical Center. The decision, which made Dana-Farber part of a growing nationwide trend of cancer centers creating cancer-specific hospitals, made sense to people who know Glimcher: “Questioning the status quo has been a hallmark of her career,” Boston Globe columnist Shirley Leung wrote in December. In the year ahead, Dana-Farber and Glimcher will also be navigating scrutiny over allegations of data manipulation in dozens of the institute’s research papers, including ones co-authored by Glimcher.
Industry
Location
-
Boston, Mass.
